Pacira BioSciences (NASDAQ:PCRX) Sets New 12-Month High Following Analyst Upgrade

Pacira BioSciences, Inc. (NASDAQ:PCRX) shares reached a new 52-week high on Thursday after Truist Financial raised their price target on the stock from $30.00 to $31.00. Truist Financial currently has a buy rating on the stock. Pacira BioSciences traded as high as $36.33 and last traded at $36.30, with a volume of 5202792 shares changing hands. The stock had previously closed at $25.20.

Several other analysts have also recently weighed in on PCRX. Needham & Company LLC lifted their price target on Pacira BioSciences from $32.00 to $33.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Wall Street Zen raised shares of Pacira BioSciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 26th. Royal Bank Of Canada boosted their price target on Pacira BioSciences from $24.00 to $25.00 and gave the company a “sector perform” rating in a research note on Wednesday, August 5th. HC Wainwright restated a “buy” rating and set a $38.00 target price on shares of Pacira BioSciences in a research note on Wednesday, July 1st. Finally, Oppenheimer started coverage on shares of Pacira BioSciences in a research note on Wednesday, September 23rd. They issued an “outperform” rating and a $32.00 price target on the stock. Four investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Pacira BioSciences presently has an average rating of “Hold” and a consensus price target of $30.29.

Insider Buying and Selling

In other news, insider Jonathan Slonin sold 3,040 shares of the company’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $23.23, for a total transaction of $70,619.20. Following the transaction, the insider owned 216,384 shares in the company, valued at approximately $5,026,600.32. This represents a 1.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.40% of the company’s stock.

More Pacira BioSciences News

Here are the key news stories impacting Pacira BioSciences this week:

• Positive Sentiment: Viatris to acquire Pacira for $36.50 per share. The offer values Pacira’s equity at approximately $1.65 billion and represents a substantial premium to the stock’s previously referenced $25.20 price. The transaction gives shareholders a defined cash-exit value, although completion remains subject to customary conditions and is expected by the end of 2026. Viatris Agrees to Acquire Pacira BioSciences
• Positive Sentiment: Viatris said the deal adds Pacira’s marketed, patent-protected EXPAREL and ZILRETTA products to its portfolio and should expand their reach through Viatris’ international infrastructure. The buyer also expects commercial and research synergies with its fast-acting meloxicam opportunity, supporting the strategic rationale for the acquisition.
• Positive Sentiment: Truist raised its price target on Pacira from $30 to $31 and maintained a “buy” rating, indicating continued analyst support before the acquisition announcement.
• Neutral Sentiment: Pacira and the Caregiver Action Network reported that families want earlier education, clearer pain-management plans and more information about non-opioid options for postsurgical recovery. The findings reinforce Pacira’s market positioning but do not directly change near-term financial results. Pacira and Caregiver Action Network Survey
• Negative Sentiment: Zacks downgraded Pacira to “strong sell,” which could have pressured the shares before the takeover news, but the cash acquisition offer is likely to dominate investor sentiment. Zacks Downgrades Pacira BioSciences

Hedge Funds Weigh In On Pacira BioSciences

Several institutional investors and hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp purchased a new position in shares of Pacira BioSciences during the second quarter worth approximately $7,532,000. Bank of America Corp DE purchased a new position in Pacira BioSciences during the 2nd quarter valued at $6,089,000. Empowered Funds LLC bought a new stake in shares of Pacira BioSciences in the 2nd quarter worth approximately $5,076,000. PDT Partners LLC purchased a new stake in shares of Pacira BioSciences in the second quarter worth $3,358,000. Finally, Man Group plc bought a new position in shares of Pacira BioSciences during the second quarter valued at $3,181,000. 99.73% of the stock is owned by institutional investors.

Pacira BioSciences Trading Up 44.0%

The stock has a market cap of $1.45 billion, a P/E ratio of 103.72 and a beta of 0.25. The company has a debt-to-equity ratio of 0.54, a current ratio of 5.04 and a quick ratio of 3.94. The firm’s 50 day moving average price is $25.18 and its 200-day moving average price is $24.41.

Pacira BioSciences (NASDAQ:PCRX) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $0.73 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.08. The firm had revenue of $192.40 million during the quarter, compared to analyst estimates of $191.06 million. Pacira BioSciences had a net margin of 1.96% and a return on equity of 9.68%. The business’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same period in the previous year, the business posted $0.74 earnings per share. As a group, equities research analysts forecast that Pacira BioSciences, Inc. will post 1.91 earnings per share for the current year.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain-management products. The company’s portfolio is designed to help manage acute and chronic pain while reducing reliance on traditional opioid therapies.

Its principal product is EXPAREL, an extended-release formulation of bupivacaine used to provide postsurgical pain relief. Pacira also markets ZILRETTA, an extended-release corticosteroid injection for osteoarthritis-related knee pain, and the iovera° system, a handheld cryoanalgesia device intended to temporarily block peripheral nerves and provide targeted pain relief.

Originally known as Pacira Pharmaceuticals, the company adopted the name Pacira BioSciences in 2018 to reflect its broader focus on innovative therapies and technologies.